PBS wait almost over for CGRP-targeted Mab

The PBAC has recommended the Authority Required (STREAMLINED) PBS listing of galcanezumab for the treatment of chronic migraine in patients who have experienced an inadequate response, intolerance or a contraindication to at least three prophylactic migraine medications. The positive recommendation from the July PBAC meeting follows a rejection earlier this year of another CGRP-targeted monoclonal ...

Already a member?

Login to keep reading.

© 2022 the limbic